Sign In
Buy BHVN
$10.81
+0.680 (+6.71%)
At Close: Jun 03, 2026
Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise
11:22am, Monday, 23'rd Sep 2024
Monday, Biohaven Ltd. BHVN released topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after three years of tr
Biohaven's stock surges as treatment slows progress of neurological disorder
09:18am, Monday, 23'rd Sep 2024
Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.
Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease
09:11am, Monday, 23'rd Sep 2024
Biohaven stock jumped Monday after the company's experimental drug slowed progression in a rare disease with no approved treatments.
Biohaven's genetic disease drug meets main trial goal
08:03am, Monday, 23'rd Sep 2024
Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
07:30am, Monday, 23'rd Sep 2024
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
07:09pm, Friday, 20'th Sep 2024
Conference call and webcast to be held Monday, September 23, at 8:30am ET NEW HAVEN, Conn. , Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
04:05pm, Thursday, 08'th Aug 2024
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advanc
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
11:48am, Friday, 26'th Jul 2024
Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
10:00am, Friday, 28'th Jun 2024
Healthcare stocks to buy have been off to the races recently — especially the ones in the weight-loss drug market. Indeed, the market is huge and could entail considerable growth for many years into
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
09:12am, Wednesday, 29'th May 2024
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platform BHV-1300 de
-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the pote
Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
03:10am, Saturday, 18'th May 2024
Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA,
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
10:35am, Tuesday, 14'th May 2024
Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
10:36am, Monday, 13'th May 2024
The heavy selling pressure might have exhausted for Biohaven Ltd. (BHVN) as it is technically in oversold territory now.
